Obsidian CEO reports major stock option holdings
Obsidian Therapeutics, Inc. director and Chief Executive Officer Madan Jagasia reported beneficial ownership of several stock options to buy Common Stock of the company.
Rhea-AI Filing Summary
Obsidian Therapeutics, Inc. director and Chief Executive Officer Madan Jagasia reported beneficial ownership of several stock options to buy Common Stock of the company. These options carry an exercise price of $0.7800 per share and various vesting schedules and expiration dates.
Holdings include stock options expiring on February 27, 2033 covering, among others, 7,081,478 underlying shares with 25% vested on January 30, 2024 and the remainder vesting in twelve equal quarterly installments, as well as additional grants that are fully vested and exercisable. Another option expiring on June 24, 2034 covers 4,154,000 underlying shares, vesting in forty-eight equal monthly installments following June 25, 2024, subject to continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
7 transactions reported
Mixed
7 txns
Insider
Jagasia Madan
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F2 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F2 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F2 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F2 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F3 | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 12,010,014 contracts (Direct)
Footnotes (3)
- F1. 25% of the shares underlying this option vested and became exercisable on January 30, 2024, with the remainder vesting in twelve (12) equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
- F2. The shares underlying this option are fully vested and exercisable.
- F3. The shares underlying this option vest in forty-eight (48) equal monthly installments following June 25, 2024, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Largest option grant underlying shares: 7,081,478 shares
Additional vested option shares: 442,592 shares
2034 grant underlying shares: 4,154,000 shares
+3 more
6 metrics
Largest option grant underlying shares
7,081,478 shares
Underlying Common Stock for stock option expiring February 27, 2033
Additional vested option shares
442,592 shares
Underlying Common Stock for fully vested and exercisable option
2034 grant underlying shares
4,154,000 shares
Underlying Common Stock for option expiring June 24, 2034
Exercise price
$0.7800 per share
Exercise price for all reported stock options
Initial vesting date (F1 grant)
January 30, 2024
25% of underlying shares vested on this date
Monthly vesting installments
48 installments
Option vesting in forty-eight equal monthly installments after June 25, 2024
Key Terms
Stock Option (Right to Buy), exercise price, vested and exercisable, expiration date, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title is listed as Stock Option (Right to Buy) for each derivative"
exercise price financial
"These options carry an exercise price of $0.7800 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vested and exercisable financial
"The shares underlying this option are fully vested and exercisable"
expiration date financial
"Reported options have an expiration date of 2033-02-27 or 2034-06-24"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Obsidian Therapeutics (OBX) disclose about Madan Jagasia on this Form 3?
Obsidian Therapeutics reported that CEO and director Madan Jagasia beneficially owns several stock options to acquire Common Stock at an exercise price of $0.7800 per share, with different vesting schedules and expiration dates.
What are the vesting terms for Madan Jagasia’s main Obsidian Therapeutics (OBX) option grant?
For one key option, 25% of the underlying shares vested on January 30, 2024, with the remaining shares vesting in twelve equal quarterly installments, conditioned on Madan Jagasia’s continued service on each vesting date.
Which of Madan Jagasia’s Obsidian Therapeutics (OBX) options are already fully vested?
Certain reported stock options, including grants covering 55,324, 110,648, and 442,592 underlying shares of Common Stock, are described as fully vested and exercisable, meaning all of their underlying shares are currently exercisable.
What are the terms of Madan Jagasia’s 2034-expiring Obsidian Therapeutics (OBX) option?
One stock option covering 4,154,000 underlying shares of Common Stock has an exercise price of $0.7800 per share, an expiration date of June 24, 2034, and vests in 48 equal monthly installments after June 25, 2024, subject to continued service.
Does this Obsidian Therapeutics (OBX) Form 3 show any stock purchases or sales by Madan Jagasia?
No buy or sell transactions are reported. The Form 3 lists existing stock option holdings and their vesting schedules, exercise price of $0.7800, and expiration dates, rather than any purchases, sales, or exercises of shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
